posted on 2019-06-27, 00:00authored byFerruccio Palazzesi, Marc A. Grundl, Alexander Pautsch, Alexander Weber, Christofer S. Tautermann
Thanks
to their unique mode of action, covalent drugs represent
an exceptional opportunity for drug design. After binding to a biologically
relevant target system, covalent compounds form a reversible or irreversible
covalent bond with a nucleophilic amino acid. Due to the inherently
large binding energy of a covalent bond, covalent binders exhibit
higher potencies and thus allow potentially lower drug dosages. However,
a proper balancing of compound reactivity is key for the design of
covalent binders, to achieve high levels of target inhibition while
minimizing promiscuous covalent binding to nontarget proteins. In
this work, we demonstrated the possibility to apply the electrophilicity
index concept to estimate covalent compound reactivity. We tested
this approach on acrylamides, one of the most prominent classes of
covalent warheads. Our study clearly demonstrated that, for compounds
with molecular weight (MW) below 250 Da, the electrophilicity index
can be directly used to estimate compound reactivity. On the other
hand, for leadlike molecules (MW > 250 Da) we implemented a new
truncation
algorithm that has to be applied before reactivity calculations. This
algorithm can ensure the localization of HOMO/LUMO orbitals on the
compound warhead and thus a correct estimation of its reactivity.
Our results also indicate that caution should be used when employing
the electrophilicity index to estimate the reactivity of nonterminal
acrylamides. The nonparametric nature of this method and its reasonable
computational cost make it a suitable tool to support covalent drug
design.